Brequinar sodium: inhibition of dihydroorotic acid dehydrogenase, depletion of pyrimidine pools, and consequent inhibition of immune functions in vitro.
Simon
P
P
Division of Inflammatory Diseases Research, Du Pont Merck Pharmaceutical Company, Wilmington, Delaware 19880-0400.
Townsend
R M
RM
Harris
R R
RR
Jones
E A
EA
Jaffee
B D
BD
D000818:Animals; D001713:Biphenyl Compounds / Q000494:pharmacology*; D002478:Cells, Cultured; D003208:Concanavalin A / Q000494:pharmacology; D004081:Dihydroorotate Oxidase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D007109:Immunity / Q000187:drug effects; D007118:Immunoassay; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D007959:Lymphocyte Culture Test, Mixed; D008214:Lymphocytes / Q000187:drug effects / Q000201:enzymology / Q000276:immunology; D009711:Nucleotides / Q000378:metabolism; D011743:Pyrimidines / Q000378:metabolism*; D051381:Rats; D011917:Rats, Inbred Lew; D013552:Swine; D013556:Swine, Miniature; D011798:Quinaldines
D001713:Biphenyl Compounds; D003208:Concanavalin A; D004081:Dihydroorotate Oxidase; D007166:Immunosuppressive Agents; D009711:Nucleotides; D011743:Pyrimidines; C046943:brequinar; D011798:Quinaldines